Characterization of TMAO productivity from carnitine challenge facilitates personalized nutrition and microbiome signatures discovery

Wei-Kai Wu,Suraphan Panyod,Po-Yu Liu,Chieh-Chang Chen,Hsien-Li Kao,Hsiao-Li Chuang,Ying-Hsien Chen,Hsin-Bai Zou,Han-Chun Kuo,Ching-Hua Kuo,Ben-Yang Liao,Tina H. T. Chiu,Ching-Hu Chung,Angela Yu-Chen Lin,Yi-Chia Lee,Sen-Lin Tang,Jin-Town Wang,Yu-Wei Wu,Cheng-Chih Hsu,Lee-Yan Sheen,Alexander N. Orekhov,Ming-Shiang Wu

DOI: https://doi.org/10.1186/s40168-020-00912-y

IF: 15.5

2020-11-19

Microbiome

Abstract:Abstract The capability of gut microbiota in degrading foods and drugs administered orally can result in diversified efficacies and toxicity interpersonally and cause significant impact on human health. Production of atherogenic trimethylamine N-oxide (TMAO) from carnitine is a gut microbiota-directed pathway and varies widely among individuals. Here, we demonstrated a personalized TMAO formation and carnitine bioavailability from carnitine supplements by differentiating individual TMAO productivities with a recently developed oral carnitine challenge test (OCCT). By exploring gut microbiome in subjects characterized by TMAO producer phenotypes, we identified 39 operational taxonomy units that were highly correlated to TMAO productivity, including Emergencia timonensis , which has been recently discovered to convert γ-butyrobetaine to TMA in vitro. A microbiome-based random forest classifier was therefore constructed to predict the TMAO producer phenotype (AUROC = 0.81) which was then validated with an external cohort (AUROC = 0.80). A novel bacterium called Ihubacter massiliensis was also discovered to be a key microbe for TMA/TMAO production by using an OCCT-based humanized gnotobiotic mice model. Simply combining the presence of E . timonensis and I . massiliensis could account for 43% of high TMAO producers with 97% specificity. Collectively, this human gut microbiota phenotype-directed approach offers potential for developing precision medicine and provides insights into translational research.

microbiology

What problem does this paper attempt to address?

This paper aims to address the issue of harmful metabolite trimethylamine N-oxide (TMAO) produced by the human gut microbiota during the metabolism of the dietary supplement betaine. Specifically, the study develops an Oral Betaine Challenge Test (OCCT) to assess an individual's ability to generate TMAO from betaine metabolism and identify microbial features associated with TMAO production. Additionally, the research explores key bacterial species in the gut microbiota that are crucial for TMAO generation and constructs a microbiome-based random forest classifier to predict whether an individual is a high TMAO producer. These findings contribute to the development of personalized nutritional recommendations and precision medicine, providing insights for translational research.